Research Reports

Key takeaways

Chief Technology Officer Eli Rosner will be terminated without cause effective April 17, 2026.

Executive Vice President Sunil Rajasekar will oversee the technology organization starting April 17, 2026.

Rosner will receive previously negotiated severance payments and benefits contingent on signing a release and complying with restrictive covenants.

Rosner's outstanding equity awards will be treated per the 2014 Stock Incentive Plan, 2024 Stock Incentive Plan, and his award agreements.

Sunil Rajasekar joined HealthEquity as Executive Vice President, Chief Product and Strategy Officer in January 2026.

Full analysis

The company is undergoing a leadership transition in its technology function, with the departure of Chief Technology Officer Eli Rosner and the expansion of responsibilities for Sunil Rajasekar, who recently joined the company in January 2026. Rajasekar brings extensive executive experience from previous roles at Billtrust, MINDBODY, eBay, and other technology companies. The termination arrangement follows standard executive compensation protocols, with severance tied to contractual agreements and equity treatment governed by existing incentive plans. This change represents a strategic realignment of technology leadership under an executive with broader product and strategy responsibilities.

HQY · HealthEquity, Inc.

Summary

Key takeaways

Full analysis